Clovis Oncology Stock News

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis Oncology (CLVS) saw its net loss narrow ~19% in Q4 2021 compared to the prior-year period even as revenue declined.

Clovis Oncology (NASDAQ: CLVS ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Clovis Oncology beat estimated earnings by 14.29%, reporting an EPS of $-0.48 versus Full story available on Benzinga.com

Clovis Oncology press release (CLVS): Q4 GAAP EPS of -$0.50.Revenue of $35.97M (-16.9% Y/Y).We have been looking forward to 2022 for a long time, which we anticipate will be the

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q4 2021 Results - Earnings Call Transcript

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is -$0.50 (+51.0% Y/Y) and

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

In the last trading session, 2.53 million shares of the Clovis Oncology Inc. (NASDAQ:CLVS) were traded, and its beta was 1.70. Most recently the company’s share price was $1.81, and it changed around -$0.09 or -4.74% from the last close, which brings the market valuation of the company to $241.49M. CLVS currently trades at a … Clovis Oncology Inc. (NASDAQ: CLVS) Stock Forecast 2022: Profitable With Bullish Signals Read More »

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

6 Top Biotech Ideas For 2022

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.